<DOC>
	<DOCNO>NCT02683564</DOCNO>
	<brief_summary>This prospective , randomize , double-blind , parallel group , multicentre global phase 3 clinical study evaluate efficacy , safety immunogenicity BOW015 ( infliximab-EPIRUS ) compare Remicade subject active Rheumatoid Arthritis ( RA ) despite Methotrexate ( MTX ) therapy .</brief_summary>
	<brief_title>BOW015 ( Infliximab-EPIRUS ) Infliximab Patients With Active Rheumatoid Arthritis : The UNIFORM Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Key 1 . Male female , age 18 80 2 . Diagnosis Rheumatoid Arthritis ( RA ) accord revise ACR/ EULAR 2010 classification criterion RA 3 . Patients must ACR/EULAR 2010 classification criterion score â‰¥ 6 4 . Patients must active disease 5 . Patients must treatment methotrexate Key 1 . Prior use infliximab , adalimumab , certolizumab , golimumab , tocilizumab , rituximab , etanercept biological treatment 2 . Patients prior current use anakinra abatacept 3 . Patients suspect confirmed current active tuberculosis ( TB ) 4 . Patients latent tuberculosis must start treatment latent tuberculosis 5 . Patients current past history chronic infection Hepatitis B , Hepatitis C , infection Human Immunodeficiency Virus1 or2 6 . History completely excise cure squamous carcinoma uterine cervix , cutaneous basal cell carcinoma cutaneous squamous cell carcinoma 7 . History lymphoproliferative disease 8 . History presence form malignancy 9 . Current sign symptom severe , progressive uncontrolled renal , hepatic , hematologic , gastrointestinal , endocrine , pulmonary , cardiac , neurologic cerebral disease 10 . History congestive heart failure unstable angina 11 . History autoimmune disease RA 12 . Major surgery within 12 week plan major surgery 13 . History serious infection 14 . Preexisting central nervous system demyelinate disorder 15 . Administration live liveattenuated vaccine within 4 week screen 16 . Clinically significant adverse reaction murine chimeric proteins 17 . History presence medical psychiatric condition disease , clinically significant laboratory abnormality 18 . Participation clinical study investigational product within previous 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>